Moderna ($MRNA ) Current Status Price: 145.04 MA5 ≈ 145.98 and MA10 ≈ 143.67 → the price is consolidating around short-term moving averages. After an extreme surge to 176.66, the price underwent a correction and is now moving sideways. MACD is weakening (histogram shrinking), indicating that bullish momentum is not building up. This surge was triggered by positive clinical trial results for Moderna's cancer vaccine (in collaboration with Merck), which caused the stock to spike by over 170% at one point. Short-term Outlook Bullish: if it breaks through 150–152, the next targets are 160 and then 176. Neutral: the most likely scenario right now is consolidation within the 138–152 range. Bearish: if it drops below 138, there is potential for a correction to 126–130. Personal probability assessment based on the chart Up: 55% Sideways: 30% Down: 15% Conclusion Currently, MRNA retains a bullish bias but remains highly volatile. The 138–140 zone serves as key support, while 150–152 acts as immediate resistance. As long as it holds above 138, the possibility of retesting the 160 level remains open. However, given the extreme nature of the previous rally, the risk of a sharp correction remains high. I lean towards a scenario of limited upside toward 150–160 rather than an immediate return to 176.